The power of prevention: how tenofovir and entecavir are changing the game in hepatocellular carcinoma

doi:10.21037/hbsn-23-528

Editorial

. 2023 Dec 1;12(6):936-940.

doi: 10.21037/hbsn-23-528. Epub 2023 Nov 9.

The power of prevention: how tenofovir and entecavir are changing the game in hepatocellular carcinoma

Endrit Shahini¹, Rossella Donghia², Antonio Facciorusso³

Affiliations

¹ Gastroenterology Unit, National Institute of Gastroenterology-IRCCS "Saverio de Bellis", Castellana Grotte, Italy.
² Data Science Unit, National Institute of Gastroenterology-IRCCS "Saverio de Bellis", Castellana Grotte, Italy.
³ Gastroenterology Unit, Department of Medical Sciences, University of Foggia, Foggia, Italy.

PMID: 38115931
PMCID: PMC10727820
DOI: 10.21037/hbsn-23-528

Editorial

The power of prevention: how tenofovir and entecavir are changing the game in hepatocellular carcinoma

Endrit Shahini et al. Hepatobiliary Surg Nutr. 2023.

. 2023 Dec 1;12(6):936-940.

doi: 10.21037/hbsn-23-528. Epub 2023 Nov 9.

Authors

Endrit Shahini¹, Rossella Donghia², Antonio Facciorusso³

Affiliations

¹ Gastroenterology Unit, National Institute of Gastroenterology-IRCCS "Saverio de Bellis", Castellana Grotte, Italy.
² Data Science Unit, National Institute of Gastroenterology-IRCCS "Saverio de Bellis", Castellana Grotte, Italy.
³ Gastroenterology Unit, Department of Medical Sciences, University of Foggia, Foggia, Italy.

PMID: 38115931
PMCID: PMC10727820
DOI: 10.21037/hbsn-23-528

No abstract available

Keywords: Hepatocellular carcinoma (HCC); cirrhosis, hepatitis B virus (HBV); liver cancer.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-23-528/coif). The authors have no conflicts of interest to declare.

Figures

**Figure 1**
Some of the essential elements of a meta-analysis study conducted in accordance with appropriate standards. Created with “BioRender.com” (Agreement number: HK25ZPG7JM, Academic License).

See this image and copyright information in PMC

Comment on

Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis.
Choi WM, Yip TC, Wong GL, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, Cant H, Chen CH, Chen CY, Huang YH, Jin YJ, Jun DW, Kim JW, Park NH, Peng CY, Shin HP, Shin JW, Yang YH, Lim YS. Choi WM, et al. J Hepatol. 2023 Mar;78(3):534-542. doi: 10.1016/j.jhep.2022.12.007. Epub 2022 Dec 23. J Hepatol. 2023. PMID: 36572349

Cited by

Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies.
Ma H, Yan QZ, Ma JR, Li DF, Yang JL. Ma H, et al. World J Gastroenterol. 2024 Mar 14;30(10):1295-1312. doi: 10.3748/wjg.v30.i10.1295. World J Gastroenterol. 2024. PMID: 38596493 Free PMC article. Review.

References

1. Choi WM, Yip TC, Wong GL, et al. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis. J Hepatol 2023;78:534-42. 10.1016/j.jhep.2022.12.007 - DOI - PubMed
1. Han Y, Zeng A, Liao H, et al. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis. Int Immunopharmacol 2017;42:168-75. 10.1016/j.intimp.2016.11.022 - DOI - PubMed
1. Zhang Z, Zhou Y, Yang J, et al. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis. BMC Cancer 2019;19:511. 10.1186/s12885-019-5735-9 - DOI - PMC - PubMed
1. Li M, Lv T, Wu S, et al. Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis. Hepatol Int 2020;14:105-14. 10.1007/s12072-019-10005-0 - DOI - PubMed
1. Gu L, Yao Q, Shen Z, et al. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis. J Gastroenterol Hepatol 2020;35:1467-76. 10.1111/jgh.15036 - DOI - PubMed

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Choi WM, Yip TC, Wong GL, et al. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis. J Hepatol 2023;78:534-42. 10.1016/j.jhep.2022.12.007 - DOI - PubMed

[2] Choi WM, Yip TC, Wong GL, et al. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis. J Hepatol 2023;78:534-42. 10.1016/j.jhep.2022.12.007 - DOI - PubMed

[3] Han Y, Zeng A, Liao H, et al. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis. Int Immunopharmacol 2017;42:168-75. 10.1016/j.intimp.2016.11.022 - DOI - PubMed

[4] Han Y, Zeng A, Liao H, et al. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis. Int Immunopharmacol 2017;42:168-75. 10.1016/j.intimp.2016.11.022 - DOI - PubMed

[5] Zhang Z, Zhou Y, Yang J, et al. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis. BMC Cancer 2019;19:511. 10.1186/s12885-019-5735-9 - DOI - PMC - PubMed

[6] Zhang Z, Zhou Y, Yang J, et al. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis. BMC Cancer 2019;19:511. 10.1186/s12885-019-5735-9 - DOI - PMC - PubMed

[7] Li M, Lv T, Wu S, et al. Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis. Hepatol Int 2020;14:105-14. 10.1007/s12072-019-10005-0 - DOI - PubMed

[8] Li M, Lv T, Wu S, et al. Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis. Hepatol Int 2020;14:105-14. 10.1007/s12072-019-10005-0 - DOI - PubMed

[9] Gu L, Yao Q, Shen Z, et al. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis. J Gastroenterol Hepatol 2020;35:1467-76. 10.1111/jgh.15036 - DOI - PubMed

[10] Gu L, Yao Q, Shen Z, et al. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis. J Gastroenterol Hepatol 2020;35:1467-76. 10.1111/jgh.15036 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The power of prevention: how tenofovir and entecavir are changing the game in hepatocellular carcinoma

Affiliations

The power of prevention: how tenofovir and entecavir are changing the game in hepatocellular carcinoma

Authors

Affiliations

Conflict of interest statement

Figures

Comment on

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources